Outcomes of Eli Lilly's attempt to get retatrutide classified as a biologic vs. a regular drug?
Health & MedicineOne-Off1yManifold MarketsNo KYCVerified resolution dataWell calibratedCurrent community forecastLilly files a Biologics License Application (BLA) for retatrutide 50%Leader of 5 outcomes
Forecasters
2
Question type
multiple choice
Methodology
Play-money forecasting platform
Source type
Forecast
7d Change
0.0 pts
Market data
Updated 6 hours ago
StaleOct 24, 26, 1:32 AM UTCDec 31, 27, 11:59 PM UTC
Trends
Related Markets
Related questions for context, not a comparison of equivalent contracts.
Will marijuana cease to be classified as a Schedule 1 drug under the U.S. Controlled Substances Act by January 1, 2030?
Manifold MarketsEli Lilly Credit Card Spend in October
KalshiWill David A. Ricks (CEO of Eli Lilly) be charged with a serious crime before 2030?
Manifold MarketsWill the climate change activists "Last Generation" ("Letzte Generation") be classified as a criminal organization?
Manifold MarketsWill Russia be classified as a "flawed democracy" by 2030?
Manifold MarketsHantavirus pandemic in 2026?
PolymarketRules
Eli Lilly wants retatrutide to be FDA approved as a biologic instead of a regular drug.
- There is an open legal question as to whether the molecule actually counts as a biologic.
- The case is currently in appeals before the Seventh Circuit.
- Arguments have been heard, and a ruling is expected soon.
- If the appeals court rules in Lilly's favor, and Lilly files a biologics license application, will the FDA actually approve retatrutide as a biologic?